NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis $5.21 +0.12 (+2.36%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Cingulate Stock (NASDAQ:CING) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cingulate alerts:Sign Up Key Stats Today's Range$5.08▼$5.3250-Day Range$4.43▼$5.8952-Week Range$3.16▼$11.89Volume97,581 shsAverage Volume145,017 shsMarket Capitalization$75.75 millionP/E RatioN/ADividend YieldN/APrice Target$27.33Consensus RatingModerate Buy Company Overview Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Read More Cingulate Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreCING MarketRank™: Cingulate scored higher than 58% of companies evaluated by MarketBeat, and ranked 406th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCingulate has a consensus price target of $27.33, representing about 424.6% upside from its current price of $5.21.Amount of Analyst CoverageCingulate has only been the subject of 4 research reports in the past 90 days.Read more about Cingulate's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cingulate are expected to grow in the coming year, from ($2.40) to ($1.02) per share.Price to Book Value per Share RatioCingulate has a P/B Ratio of 16.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.31% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 10.02, which indicates bearish sentiment.Change versus previous monthShort interest in Cingulate has recently decreased by 6.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment1.01 News SentimentCingulate has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cingulate this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have not sold or bought any company stock.Percentage Held by Insiders5.30% of the stock of Cingulate is held by insiders.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CING Stock News HeadlinesPsychedelic drug calms hyperactive brain cells linked to chronic painAugust 16 at 7:12 PM | msn.comCingulate (NASDAQ:CING) Raised to Sell at Wall Street ZenAugust 15 at 2:01 AM | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 17 at 1:00 AM | Investors Alley (Ad)Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million CashAugust 13, 2026 | quiverquant.comQCingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessAugust 13, 2026 | globenewswire.comCingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic ProfileAugust 11, 2026 | markets.businessinsider.comCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent PsychopharmacologyJuly 30, 2026 | globenewswire.comCingulate enhances equity plan and updates board leadershipJuly 15, 2026 | tipranks.comSee More Headlines CING Stock Analysis - Frequently Asked Questions How have CING shares performed this year? Cingulate's stock was trading at $4.34 at the start of the year. Since then, CING stock has increased by 20.0% and is now trading at $5.21. How were Cingulate's earnings last quarter? Cingulate Inc. (NASDAQ:CING) issued its earnings results on Thursday, August, 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.18. When did Cingulate's stock split? Shares of Cingulate reverse split before market open on Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share. Who are Cingulate's major shareholders? Cingulate's top institutional investors include BlackRock Inc. (0.39%). Insiders that own company stock include Peter J Werth, Thomas Jeffrey Hargroves, Shane J Schaffer, Jennifer L Callahan, Matthew Brams and Laurie Myers. View institutional ownership trends. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cingulate own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Company Calendar Last Earnings8/13/2026Today8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CING's financial health is in the Yellow zone, according to TradeSmith. CING has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CING CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Cingulate$27.33 High Price Target$52.00 Low Price Target$10.00 Potential Upside/Downside+424.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-238.40% Return on Assets-128.67% Debt Debt-to-Equity RatioN/A Current Ratio3.50 Quick Ratio3.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book16.81Miscellaneous Outstanding Shares14,540,000Free Float13,771,000Market Cap$75.75 million OptionableNot Optionable Beta-0.90 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CING) was last updated on 8/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
